Companies with diverse infectious disease diagnostic technology offerings said that molecular methods are complementary to, not competitive with traditional diagnostics.
Abbott's commitment to closing the deal is still uncertain, but Alere's CEO said the regulatory clearance marks a "significant milestone."
Mergers and acquisitions in the omics space rose for the second year in a row, but the increase was significantly less than the 33 percent uptick in 2015 deals.
Alere said its would-be acquirer has no grounds for seeking termination, but Abbott cited adverse material events as a basis for ending the deal.
The GenomeWeb Index, which fell nearly 9 percent in October, rebounded to a 1 percent gain in November, but still underperformed the Dow and Nasdaq.
Abbott said that a lawsuit it filed Thursday tries to obtain important information from Alere before its acquisition is completed.
The GenomeWeb Index fell nearly 9 percent in October, doubling back on September's 5 percent gain and underperforming the Dow and the Nasdaq.
Shareholder approval follows China's avowal that it will not block the deal and Abbott's CEO confirming his faith in Alere's business.
CEO Miles White said that he still believes that Alere is a good strategic fit for Abbott, and the firm is pursuing all of the necessary regulatory approvals for the deal.
The court order provided a schedule of actions designed to resolve antitrust issues related to the deal.
In Science this week: intellectual property landscape of CRISPR genome editing, and more.
A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.
Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.
Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.